In Brief: Medtronic
This article was originally published in The Gray Sheet
Medtronic: Receives FDA approval for the Model 4965 steroid-eluting pacemaker lead for infants and children. The lead is expected to reduce scarring, inflammation at the contact point, and the intensity of the electrical impulse needed to stimulate the heartbeat, the firm says. Available in sizes for infants, children and adults, the Model 4965 "completes Medtronic's product line of steroid-eluting leads," Medtronic says, complementing the firm's Capture, Capture Z and Capture Fix products...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.